Ipsen S.A.'s latest marketcap:
As of 06/23/2025, Ipsen S.A.'s market capitalization has reached $9.64 B. According to our data, Ipsen S.A. is the 1962th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 9.64 B |
| Revenue (ttm) | 4 B |
| Net Income (ttm) | 386.82 M |
| Shares Out | 0 |
| EPS (ttm) | 4.64 |
| Forward PE | 9.66 |
| Ex-Dividend Date | 06/04/2025 |
| Earnings Date | 07/31/2025 |
Ipsen S.A.'s yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/23/2025 | £9.64 B | -5.67% | 1962 |
| 12/31/2024 | £7.57 B | -2.11% | 1788 |
| 12/29/2023 | £7.73 B | 5.32% | 1646 |
| 12/30/2022 | £7.34 B | 32.06% | 1666 |
| 12/31/2021 | £5.56 B | 10.66% | 2303 |
| 12/31/2020 | £5.03 B | -9.59% | 2209 |
| 12/31/2019 | £5.56 B | -33.19% | 1749 |
| 12/31/2018 | £8.32 B | 14.35% | 1065 |
| 12/29/2017 | £7.28 B | 50.55% | 1332 |
| 12/30/2016 | £4.83 B | 30.59% | 1651 |
Company Profile
About Ipsen S.A.
Ipsen S.A. is a global biopharmaceutical company specializing in innovative treatments across oncology, neuroscience, and rare diseases. Founded in 1929 and headquartered in Boulogne-Billancourt, France, Ipsen is committed to advancing patient care through cutting-edge therapies.
Key Therapeutic Areas & Products
- Oncology: Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik
- Neuroscience: Dysport and other neurotoxin-based treatments
- Rare Diseases: Bylvay, NutropinAq, Increlex, Sohonos
Pipeline Highlights
- Phase III: Cabometyx + Atezolizumab (metastatic prostate cancer), Taverik (follicular lymphoma), Bylvay (biliary atresia), Dysport (chronic/episodic migraine)
- Phase II: Fidrisertib (fibrodysplasia ossificans progressiva), Elafibranor (primary sclerosing cholangitis), IPN10200 (longer-acting neurotoxins)
- Phase I: IPN60210 (relapsed/refractory multiple myeloma), IPN60260 (viral cholestatic disease)
Ipsen continues to drive innovation in biopharmaceuticals, addressing unmet medical needs with a robust pipeline and established therapies.
Frequently Asked Questions
-
What is Ipsen S.A.'s (LON-0MH6) current market cap?As of 06/23/2025, Ipsen S.A. (including the parent company, if applicable) has an estimated market capitalization of $9.64 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Ipsen S.A. (LON-0MH6) rank globally by market cap?Ipsen S.A. global market capitalization ranking is approximately 1962 as of 06/23/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.